A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Completed

Conditions studied: Pulmonary Disease, Chronic Obstructive

In brief

To compare the persistence in using two different medications from the same drug class (LAMA/LABA FDC) which are delivered through different devices, a dry-powder inhalers (DPI) and Soft Mist Inhalers (SMI).

Key facts

Study ID

NCT03979807

Run by

Boehringer Ingelheim

People needed

11296

Starts

2019-06-10

Expected to finish

2019-06-11

Last updated by the study team

2021-11-15

Who can join

Age: 1 and older, up to 40. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Aged <40 years
• Enrolment with medical and pharmacy coverage prior to the cohort entry < 180 days
• Never had COPD diagnosis on the cohort entry date or prior to cohort entry
• A record for dispensed Olodaterol/Tiotropium Bromide delivered with Respimat inhalator or Umeclidinium/Vilanterol delivered with the Ellipta Inhaler during the 180-day baseline prior to cohort entry
• Diagnosis of asthma any time prior to cohort entry
• Diagnosis of lung cancer any time prior to cohort entry
• Diagnosis of lung transplant any time prior to cohort entry

Where it is running

• Aetion Inc. — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.